Sir Andrew Witty, CEO of GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies, advocates for drug pricing transparency in a video interview with Cristina Alesci of CNNMoney.
Opening the discussion, Alesci points out how the presidential candidates are openly talking about drug pricing.
Alesci: “What do you think this means for your industry, especially because the U.S., as you said, is your biggest market? That [drug pricing] is all we hear about these days, from Donald Trump, to Hillary Clinton, to Bernie Sanders—they’re all talking about how the price of drugs has to come down.”
Witty: “… The issue, as much as anything, is the cost of healthcare, not just the cost of drugs. Remember, drugs are probably 10-15 percent of the total healthcare bill, but healthcare is 17 percent of U.S. GDP.”
Watch the video below to hear more of their conversation.
Video caption: Sir Andrew Witty tells CNNMoney’s Cristina Alesci about the challenges surrounding the pharmaceutical space and why we need more drug pricing transparency in the U.S.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
